About Matrilin-1
Matrilin-1 (MATN1) is a protein
from Homo sapiens identified by UniProt accession
P21941, 496 residues long.
MolForge cross-references it against 0 known binders and
88 disease associations.
Target properties
| Protein name | Matrilin-1 |
| UniProt accession | P21941 |
| Gene | MATN1 |
| Organism | Homo sapiens |
| Length | 496 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (88)
Diseases linked to this target (Open Targets).
- body height · score 0.43
- monocyte count · score 0.39
- myeloid white cell count · score 0.25
- high density lipoprotein cholesterol measurement · score 0.24
- breast adenocarcinoma · score 0.20
- adolescent idiopathic scoliosis · score 0.18
- platelet crit · score 0.17
- leukocyte count · score 0.14
- nose morphology measurement · score 0.10
- peak expiratory flow · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P21941-F1 | alphafold | PREDICTED | 83.11 | — |
Amino-acid sequence (496 residues)
MRVLSGTSLM LCSLLLLLQA LCSPGLAPQS RGHLCRTRPT DLVFVVDSSR SVRPVEFEKV KVFLSQVIES LDVGPNATRV GMVNYASTVK QEFSLRAHVS KAALLQAVRR IQPLSTGTMT GLAIQFAITK AFGDAEGGRS RSPDISKVVI VVTDGRPQDS VQDVSARARA SGVELFAIGV GSVDKATLRQ IASEPQDEHV DYVESYSVIE KLSRKFQEAF CVVSDLCATG DHDCEQVCIS SPGSYTCACH EGFTLNSDGK TCNVCSGGGG SSATDLVFLI DGSKSVRPEN FELVKKFISQ IVDTLDVSDK LAQVGLVQYS SSVRQEFPLG RFHTKKDIKA AVRNMSYMEK GTMTGAALKY LIDNSFTVSS GARPGAQKVG IVFTDGRSQD YINDAAKKAK DLGFKMFAVG VGNAVEDELR EIASEPVAEH YFYTADFKTI NQIGKKLQKK ICVEEDPCAC ESLVKFQAKV EGLLQALTRK LEAVSKRLAI LENTVV
Explore Matrilin-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets